New research indicates GLP1-RA medications do not increase thyroid cancer risk, reassuring users and clinicians. A new study, ...

Being overweight raises your risk of thyroid cancer ... One study reported that the incidence of thyroid cancer in semaglutide-treated patients was less than 1%. As of now, the FDA warning ...

A new analysis of FDA adverse event reports suggests a potential link between tirzepatide and thyroid cancer. Learn what this ...

The following text highlights some of these precautions. Boxed warning: Risk of thyroid cancer Semaglutide (the active ingredient in Ozempic and Wegovy) has a boxed warning for a possible risk of ...

Drugs originally developed to treat type 2 diabetes, particularly GLP-1 receptor agonists such as semaglutide (sold as ...

Rybelsus (semaglutide) and Ozempic (semaglutide ... whether any of these warnings apply to you. Boxed warning: Risk of thyroid cancer Rybelsus and Ozempic have a boxed warning for the risk ...

Animal studies have shown that using liraglutide (the active ingredient in Saxenda) or semaglutide (the active ingredient in Ozempic) may increase the risk of thyroid cancer. However, the risk of ...

For patients with diabetes, semaglutide use is associated with an increased risk for nonarteritic anterior ischemic optic ...